幽门螺杆菌根除后新发或长期低剂量阿司匹林使用者胃肠道出血住院的发生率、时间趋势及风险:一项全地区队列研究
基于全地区健康数据库,纳入2003至2012年间首次接受克拉霉素三联疗法的患者,分为新发阿司匹林使用者、长期使用者和非使用者。新发使用者发生所有胃肠道出血住院的风险高于长期使用者(倾向性评分匹配HR 1.89,95%CI 1.29至2.70),且风险升高仅见于前6个月。根除幽门螺杆菌的阿司匹林使用者中下消化道出血比上消化道出血更常见。
要点
- 新发阿司匹林使用者胃肠道出血风险高于长期使用者(HR 1.89,95%CI 1.29至2.70)。
- 新发使用者风险升高仅见于前6个月(所有胃肠道出血HR 2.10,95%CI 1.41至3.13;上消化道出血HR 2.52,95%CI 1.38至4.60)。
- 根除幽门螺杆菌的阿司匹林使用者中下消化道出血(45.3%)比上消化道出血(34.7%)更常见。
核心结论
- 新发阿司匹林使用者胃肠道出血风险高于长期使用者,尤其在前6个月内。
- 根除幽门螺杆菌的阿司匹林使用者中下消化道出血比上消化道出血更常见。
研究设计与样本
- 基于全地区健康数据库的队列研究,纳入2003至2012年间首次接受克拉霉素三联疗法的患者。
- 按阿司匹林使用分为新发使用者6985例、长期使用者5545例和非使用者48908例。
- 主要结局为胃肠道出血住院风险。
主要发现
- 新发、长期和非使用者所有胃肠道出血住院的年龄和性别调整发生率分别为10.4、7.2和4.6每1000人年。
- 上消化道出血和下消化道出血分别占所有出血的34.7%和45.3%。
- 与长期使用者相比,新发使用者胃肠道出血风险更高(倾向性评分匹配HR 1.89,95%CI 1.29至2.70)。
- 界标分析显示新发使用者风险升高仅见于前6个月的所有胃肠道出血(HR 2.10,95%CI 1.41至3.13)和上消化道出血(HR 2.52,95%CI 1.38至4.60),下消化道出血未见风险升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The risk of GI bleeding (GIB) in aspirin users after Helicobacter pylori (HP) eradication remains poorly defined. We characterised the incidences and temporal trends of hospitalisations for all GIB in aspirin users after HP eradication therapy. DESIGN: Based on a territory-wide health database, we identified all patients who had received the first course of clarithromycin-based triple therapy between 2003 and 2012. Patients were divided into three cohorts according to aspirin use: new users (commenced after HP eradication), chronic users (commenced before and resumed after HP eradication) and non-users. The primary outcome was to determine the risk of hospitalisation for GIB. RESULTS: We included 6985 new aspirin users, 5545 chronic users and 48 908 non-users. The age-adjusted and sex-adjusted incidence of hospitalisation for all GIB in new, chronic and non-users was 10.4, 7.2 and 4.6 per 1000 person-years, respectively. Upper and lower GIB accounted for 34.7% and 45.3% of all bleeding, respectively. Compared with chronic users, new users had a higher risk of GIB (HR with propensity score matching: 1.89; 95% CI 1.29 to 2.70). Landmark analysis showed that the increased risk in new aspirin users was only observed in the first 6 months for all GIB (HR 2.10, 95% CI 1.41 to 3.13) and upper GIB (HR 2.52, 95% CI 1.38 to 4.60), but not for lower GIB. CONCLUSION: New aspirin users had a higher risk of GIB than chronic aspirin users, particularly during the initial 6 months. Lower GIB is more frequent than upper GIB in aspirin users who had HP eradicated.
引用
- Guo CG, Cheung KS, Zhang F, et al. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study. Gut. 2019. PMID: 31101690. doi:10.1136/gutjnl-2019-318352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。